Compare VYX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | ANAB |
|---|---|---|
| Founded | 1881 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2017 |
| Metric | VYX | ANAB |
|---|---|---|
| Price | $11.03 | $44.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $15.17 | ★ $58.09 |
| AVG Volume (30 Days) | ★ 1.6M | 501.4K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,653,000,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $7.55 | $12.21 |
| 52 Week High | $14.67 | $52.47 |
| Indicator | VYX | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 49.32 |
| Support Level | $10.15 | $42.00 |
| Resistance Level | $10.62 | $47.36 |
| Average True Range (ATR) | 0.36 | 2.46 |
| MACD | 0.08 | -0.90 |
| Stochastic Oscillator | 99.20 | 26.41 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).